European Medicines Agency (EMA) | What's new

Opinion/decision on a Paediatric investigation plan (PIP): Supemtek Tetra (previously Supemtek), recombinant Influenza Hemagglutinin-strain A (H1N1 subtype),recombinant Influenza Hemagglutinin-strain A (H3N2 subtype),recombinant Influenza Hemagglutinin-strain B (Victoria lineage),recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) (RIV4), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP numb...

Opinion/decision on a Paediatric investigation plan (PIP): Supemtek Tetra (previously Supemtek), recombinant Influenza Hemagglutinin-strain A (H1N1 subtype),recombinant Influenza Hemagglutinin-strain A (H3N2 subtype),recombinant Influenza Hemagglutinin-strain B (Victoria lineage),recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) (RIV4), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0098/2024
favicon
ema.europa.eu
ema.europa.eu